Categories AlphaGraphs, Earnings, Health Care
Merck (MRK) sales decline 8% in Q2 2020; raises FY20 outlook
Merck (NYSE: MRK) reported an 8% drop in second quarter sales, reflecting the negative impact of COVID-19. However, sales of $10.9 billion and adjusted EPS of $1.37 topped Street’s views. The pharma giant lifted its outlook for fiscal 2020.
MRK stock rose about 3% in the pre-market trading session following its earnings announcement.

Merck narrowed and lifted FY20 revenue guidance to a range of $47.2 billion to $48.7 billion.
The Kenilworth, New Jersey-based firm also narrowed and raised its earnings outlook for FY20. GAAP EPS is now expected to be between $4.58 and $4.73 and non-GAAP EPS is now expected to be between $5.63 and $5.78.
Merck is accelerating two COVID-19 vaccine development efforts and a novel antiviral candidate. “We are conscious of our abiding responsibility to help advance vaccine and antiviral efforts as part of the global response to SARS-CoV-2 and to ensure broad, equitable and affordable global access to any medicines and vaccines we bring forward,” said CEO Kenneth Frazier.
Most Popular
Infographic: How Starbucks (SBUX) performed in Q1 2023
Starbucks Corporation (NASDAQ: SBUX) reported first quarter 2023 earnings results today. Consolidated net revenues increased 8% year-over-year to $8.7 billion, in line with projections. Global comparable store sales increased
Earnings: Google parent Alphabet (GOOG, GOOGL) reports lower Q4 profit
Alphabet Inc. (NASDAQ: GOOGL, GOOG) on Thursday reported a 1% increase in fourth-quarter 2022 revenues, with strong contributions from the cloud business. The company, which owns the largest internet search
HOG Earnings: Key quarterly highlights from Harley-Davidson’s Q4 2022 financial results
Harley-Davidson, Inc. (NYSE: HOG) reported fourth quarter 2022 earnings results today. Revenue increased 12% year-over-year to $1.14 billion. Net income attributable to Harley-Davidson, Inc. rose 94% YoY to $42 million,